GLPG1690 is primarily investigated for its potential therapeutic applications in treating idiopathic pulmonary fibrosis (IPF), a chronic and progressive lung disease. It functions as an autotaxin inhibitor, targeting the enzyme autotaxin, which plays a role in the production of lysophosphatidic acid (LPA). Elevated levels of LPA are associated with fibrosis, inflammation, and tissue remodeling in IPF. By inhibiting autotaxin, GLPG1690 aims to reduce LPA levels, thereby slowing disease progression and improving lung function. Clinical trials have explored its efficacy and safety, showing promise in reducing fibrosis and improving patient outcomes. Additionally, research is ongoing to evaluate its potential in other fibrotic or inflammatory conditions beyond IPF.